Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
Holding IOBT?
Track your performance easily
IOBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.66 - $2.10
Previous Close$0.77
Volume214.72K
Average Volume (3M)345.49K
Market Cap
$50.08M
Enterprise Value-$28.09M
Total Cash (Recent Filing)$80.19M
Total Debt (Recent Filing)$2.02M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 27, 2025EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding65,880,914
10 Day Avg. Volume266,563
30 Day Avg. Volume345,487
Standard Deviation0.23
R-Squared0.00353
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$8.67Price Target Upside1024.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
IO Biotech News
PremiumCompany Announcements
IO Biotech Secures €57.5 Million EIB Loan Facility
Bulls Say, Bears Say
Bulls Say
Clinical Data SuccessThe Phase 1 study indicated that IO102-IO103 combined with nivolumab showed a progression-free survival (PFS) of 22.5 months, which is a significant improvement compared to the expected 11-12 months with checkpoint inhibitors alone.
Financial StabilityEnded 3Q24 with $80.2M in cash, which is expected to support operations into 4Q25.
Regulatory MilestonesPositive topline results from the Phase 3 study are expected to support full approval and filing for IO102-IO103 in first-line melanoma treatment.
Bears Say
Safety ConcernsThe safety profile showed Grade 3-4 treatment-related adverse events in 24% of patients, which is slightly higher than some comparable studies.
Study ResultsThe interim results from the Phase 3 study did not meet statistical significance, and there is uncertainty regarding the numerical benefit in the treatment arm as the ORR numbers were not disclosed.
Treatment EfficacyIO102-IO103 appears to be marginally additive to pembro alone based on KEYNOTE-024 and -042 studies, with an updated ORR that is only marginally additive to pembro alone of less than 10%.
---
Ownership Overview
28.02% Insiders
0.83% Mutual Funds
26.23% Other Institutional Investors
44.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is IO Biotech’s market cap?
Currently, no data Available
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Nov 12, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.288 by -$0.072.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate is -$0.39.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.288. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at N/A.
---
IO Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (1024.51% Upside)
$8.67 (1024.51% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.90%
12-Months-Change
Fundamentals
Return on Equity
-78.50%
Trailing 12-Months
Asset Growth
-47.87%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
---
IOBT Stock 12 Month Forecast
Average Price Target
$8.67
▲(1024.51% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kala Pharmaceuticals
―
TG Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-34.09%
assigned a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.09% per trade.
---